Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid tetanus toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid tetanus vaccine adsorbed - %v/v

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)); diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =) - suspension for injection - active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)) excipient: lactose monohydrate sodium chloride water active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide phenoxyethanol sodium chloride water for injection - infanrixtm-hib is indicated for active immunisation against diphtheria, tetanus, pertussis (dtp) and haemophilus influenzae type b (hib) infection in all children from 15 months of age.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - diphtheria toxoid (dt) >= 30 iu/dose; poliovirus type 2 (inactivated) 8 d-antigen u/0,5 ml; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; poliovirus type 1 (inactivated) 40 d-antigen u/0,5 ml; tetanus toxoid >= 40 iu/dose; bordetella pertussis toxoid (pt) 25 µg/dose; bordetella pertussis pertactin 8 µg/dose; poliovirus type 3 (inactivated) 32 d-antigen u/0,5 ml - suspension for injection - diphteria antigen, adsorbed; poliomyelitis virus; tetanus toxoid adsorbed; bordetella pertussis antigen, proteins - diphtheria-pertussis-poliomyelitis-tetanus

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - poliovirus type 2 (inactivated) 8 d-antigen u/1 dose; poliovirus type 3 (inactivated) 32 d-antigen u/1 dose; poliovirus type 1 (inactivated) 40 d-antigen u/1 dose; bordetella pertussis pertactin 8 µg/dose; tetanus toxoid >= 40 iu/dose; bordetella pertussis filamentous hemagglutinin (fha) 25 µg/dose; bordetella pertussis toxoid (pt) 25 µg/dose; diphtheria toxoid (dt) >= 30 iu/dose; conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid - powder and solvent for suspension for injection - diphteria antigen, adsorbed; haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; poliomyelitis virus; tetanus toxoid adsorbed; bordetella pertussis antigen, proteins - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - crm197 protein; pneumococcal polysaccharide serotype 1 (conjugate); pneumococcal polysaccharide serotype 14 (conjugate); pneumococcal polysaccharide serotype 18c (conjugate); pneumococcal polysaccharide serotype 19a (conjugate); pneumococcal polysaccharide serotype 19f (conjugate); pneumococcal polysaccharide serotype 23f (conjugate); pneumococcal polysaccharide serotype 3 (conjugate); pneumococcal polysaccharide serotype 4 (conjugate); pneumococcal polysaccharide serotype 5 (conjugate); pneumococcal polysaccharide serotype 6a (conjugate); pneumococcal polysaccharide serotype 6b (conjugate); pneumococcal polysaccharide serotype 7f (conjugate); pneumococcal polysaccharide serotype 9v (conjugate) - injection, suspension - 32mcg - crm197 protein 32mcg; pneumococcal polysaccharide serotype 1 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 14 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 18c (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 23f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 3 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 4 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 5 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6b (conjugate) 4.4mcg; pneumococcal polysaccharide serotype 7f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 9v (conjugate) 2.2mcg

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; tetanus toxoid, quantity: 40 iu/ml; diphtheria toxoid, quantity: 4 iu/ml; pertactin, quantity: 5 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; aluminium phosphate; sodium chloride - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

wyeth pharmaceuticals - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 4.4mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - poliovirus; pertactin; pertussis filamentous haemagglutinin; pertussis toxoid; diphtheria toxoid; hepatitis b surface antigen recombinant; tetanus toxoid -